Professional Acitivities

• Primary academic appointments: Department of Pediatrics, College of Osteopathic Medicine; Microbiology and Molecular Genetics, College of Osteopathic Medicine
• Secondary appointments: University Wide Program in Genetics, University Wide Program in Cell and Molecular Biology
• Present academic rank and title:  Osteopathic Heritage Foundation (Tenured) Professor of Microbiology and Molecular Genetics and Pediatrics
• Date and rank of Michigan State University  faculty appointment: 9/01/2005: Full Professor (Tenured)
• Medical licensure: State of Michigan Perm. ID # 5101011076: Status: Active
• Diplomate of the American Board Medical Genetics (DABMG) Maintenance of certification dates: Clinical Genetics: 9/96, Recertified 03/2006,2009

Scholarly societies:

• American Society of Microbiology
• American Society of Gene Therapy
• Fellow, American College of Medical Genetics
• Diplomate, American Board of Medical Genetics
• American Osteopathic Association
• Michigan Osteopathic Association

Editorial Activities:

• Editorial  Board:
• Molecular Therapy: The Journal of the American Society of Gene and Cell Therapy
• Gene Therapy
• Editorial Advisory Board: Current Gene Therapy
• Invited outside expert/reviewer: Selected Journals include:
• American Journal of Medical Genetics
• Bio-techniques
• Biochimica et Biophysica Acta: Molecular Basis of Disease
• Biotechnology Progress
• Expert Opinion on Biological Therapy
• Expert Review of Vaccines
• Gene
• Gene Tests
• Gene Therapy
• Human Gene Therapy
• Human Molecular Genetics
• International Journal Of Cancer
• In Vitro Cellular & Developmental Biology
• Journal of Clinical Investigation
• Journal of Cellular Physiology
• Journal of Gene Medicine
• Journal of Microbiology and Antimicrobials
• Journal of Immunology
• Journal of Pharmacology and Experimental Therapeutics
• Journal of Virological Methods
• Journal of Virology
• Lancet
• Molecular Genetics and Metabolism
• Molecular Medicine
• Muscle and Nerve
• PLoS One
• Proceedings of the National Academy of Sciences (USA)
• Transgenic Research
• Trends in Biotechnology
• Vaccine

Professional awards, invited speaker, and other special recognitions:

• Invited Speaker, CS Mott Childrens Hospital, University of Michigan Medical Center, Dept. of Pediatrics Grand Rounds. "Update on Pompe disease: Pathogenesis, Treatment, Newborn Screening, and Gene Therapy. Sep. 2014.
• Invited Speaker, Helen DeVos Childrens Hospital, Pediatric Department Grand Rounds: Translational Research and Pompe Disease. May 2014.
• Invited Speaker, 2013 Merial-NIH Veterinary Scholars Symposium., "A Unique Colon Cancer Vaccine". East Lansing, MI, August, 2013.
• Invited Speaker, Annual meeting of the American Society of Gene And Cell Therapy. Scientific Symposium on Vaccine Frontiers:  "Advancing Vaccines with Use of Adenovirus Based Gene Transfer Vectors". Philadelphia PA. May, 2012
• J.O. Watson D.O. Lecturer/awardee, Ohio Osteopathic Association and the Osteopathic Heritage Foundation. Invited Lecturer 2012 Ohio Osteopathic Association Annual Meeting "Expanding the Frontiers of Osteopathic Research to address 21st Century Medical Needs". Columbus Ohio, April 20, 2012.
• Big Ten Network "Medical Impact Series" highlights Dr. Amalfitano's accomplishments as a physician-scientist at a  Big Ten University. March 2012.
• Invited Speaker, 2011 Acid Maltase Deficiency Association/ International Pompe Association Patient and Scientific Conference. " Past, Present, and Future of Gene Therapy for Pompe Disease. San Antonio, TX, Oct 8-9, 2011.
• Danny Thomas Lecture Series 2010 Visiting Professor. St. Jude Children's Research Hospital, "Delineating Adenovirus vector interactions with the immune system facilitates improved efficacy in both Gene Therapy and Vaccine applications". Memphis, TN., Dec 3, 2010.
• Keynote Address:PRIM &R's 2010 IACUC Conference . "Biomedical Research into Treatment of Genetic and Infectious Diseases", Baltimore, MD. March 23, 2010.
• Keynote Address, St Vincent Mercy Medical Center Annual Research Day. “Translational Research” .May 13, 2009.
• Invited Speaker: “Adenovirus Vector based Gene Transfer: Benefits and Limitations”. Department of Medical and Molecular Genetics, Indiana University/Purdue University-Indianapolis Medical Center. Aug 27, 2008.
• Organizer : Mini-symposium on Gene Transfer. Current Clinical and Pre-clinical advancements. Symposium featuring top investigators in the field of clinical gene transfer,  held at Michigan State University. 2008.
• Invited Speaker: Gordon Research Conference on the Science of Viral Vectors for Gene Therapy: The Host Response to Viral Infection.  Adaptive Immune Responses to Viral Infection: “Adenovirus interactions with the Innate and Adaptive Arms of the Immune System. March 2-7, 2008.
• Invited Speaker: Pompe Disease: Pathogenesis, Genetics, and Treatment Strategies, Grand Rounds, Dept. of Neurology, University of Toledo Health Sciences Center, 2008
• Invited, Symposium Moderator: American Society of Gene Therapy, Session on Gene Therapy and Inherited Disease (declined due to scheduling conflict).2008
• Invited Speaker: WTEC Study on Vaccine Manufacturing: Workshop on Science and Technology in North American Rapid Vaccine Manufacturing: Concepts Regarding Adenovirus Based Vaccine Systems”. Arlington VA.2007.
• Invited, Symposium Moderator: American Society of Gene Therapy, Session on Innate Immune Responses to Viral Vectors, 2007.
• Invited Speaker- Current Advances in therapy of Pompe Disease, MDA musculoskeletal clinics in San Francisco, Chicago, and Detroit, 2006-2007
• Invited Speaker and Participant , Symposium Workshop on “Muscle Glycogenoses”, October 2007, Genoa-Quarto, Italy, 2006
• -Osteopathic Heritage Foundation Endowed Professor, Michigan State University, 2005.
• -Invited Speaker –Pediatric Academic Societies 2005 Annual Meetings, Washington, DC. May, 2005.Virus-Host Interactions: Mechanisms Underlying Persistent viral infections: PAS/PIS Topic Symposium Adenovirus Based Vectors as Tools to Understand Viral Persistence  “Applying Viral Immune evasion strategies to adenovirus gene therapy vectors”.
• Invited Speaker AGSD (UK) Patient Conference and International Pompe Association Meeting Birmingham, United Kingdom, Oct 9-10, 2004.
• Invited Speaker, University Of Alabama-Birmingham, Gene Therapy Institute, Lecture Series on Gene Therapy Initiatives/Research: “Adenovirus gene transfer, Potential and Limitations” Sep 28,2004.
• Invited Speaker: Adenovirus  interactions with the complement systems of humans and mice.  H. Jiang, R.Everett, A. Kiang, Z. Wang, H. Zhang, D.Serra,  M.M. Frank, and A.Amalfitano.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
• Invited Speaker: Acid-Maltase Disease Association Teleconference for Patients: “Gene Therapy and Pompe Disease” Mar 23, 2004.
• Invited Speaker: Mid-winter meeting of the Association for Research in Otolaryngology, Feb 2004. “Virally Mediated Gene Transfer, from Virology to Practice-Modified Adenovirus vectors offer multiple advantages for gene transfer research”.  Daytona, Florida.2004
• Invited Speaker: 11th Annual meeting of the European Society of Gene Therapy, Nov 2003. “Complement and Adenovirus vectors”.  Edinburgh, Scotland
• Invited Speaker: 2nd annual meeting of the International Pompe Association: Oct 2003: Heidelberg, Germany “Gene Therapy for Pompe Disease”.
• Invited Speaker: Cardiovascular Gene Transfer Symposium.  5th Annual Meeting of the American Society of Gene Therapy 2002, Washington, D.C.
• Invited Speaker: Educational Symposium on Adenovirus Vectors. Multiply-Deleted Ad Vectors, Clinical Trials and Immunological Responses to Vector Delivery.  5th Annual Meeting of the American Society of Gene Therapy 2002, Washington, D.C.
• Invited Speaker: The 2nd International Symposium on DNA Vaccine and Gene Therapy Technology.   "Optimization of Adenovirus based vectors for multiple gene transfer approaches";  December 12-14, 2002.  Taipei, Taiwan.
• Invited Speaker: North Carolina Pediatric Society Annual Meeting, Sep 2002, “Gene therapy: Where have we been and where are we going?
• Awardee: NIH/NICHD Pediatric Research Loan Repayment Program, with annual competitive renewals awarded :Sep 2002-2006.
• Invited Speaker: Plenary Session, 5th Annual Meeting of the American Society of Gene Therapy, June 2002
• Invited Plenary Session  (Advances in Pre-clinical Research) Speaker at 2002 HIV Vaccine Trials Network Full Group Meeting, “Adenovirus biology and why are they good vectors”: Alexandria, VA:May 2002.
• Invited Speaker: 2001 Think Tank Symposium on Gene Therapy for Eye Diseases: “Benefits and Limitation of Adenovirus based gene transfer for ocular disorders” Sponsored by the Glaucoma Foundation. New York, New York, USA.
• Co-led “first-in-man” Phase I/II Clinical Trial of Myozyme enzyme infusion therapy for infantile Pompe Disease. Duke University Medical Center, Durham, NC.  Myozyme subsequently approved for human use by FDA in April 2006 as a direct result of this and othersubseqent clinical trials.
• Invited Speaker: National Taiwan University Hospital: Applications of Gene Therapy to Human Diseases. 2001.
• Invited Speaker: Taiwan Center for Drug Evaluation, (Taiwan FDA equivalent).  “Understanding Adenovirus based vectors and their potential for safe, clinical use”. 2001.
• 2001 Michigan State University College of Osteopathic Medicine Alumni of the Year Award.
• Invited Speaker: Plenary Session, 4th Annual Meeting of the American Society of Gene Therapy, June 2001
• Invited Speaker, University of North Carolina at Chapel Hill, Dept of Gene Therapy, “Utilization of Adenovirus based Vectors. 2000.
•  “Adenovirus vector gutted” Nature Biotechnology “Research News Briefs” highlighting findings published by Amalfitano Lab.   Nature Biotechnology: Vol 17 pp: 317: 1999,
• Invited Speaker: Scientific Symposium on Nonintegrating viral Vectors.  “Improvements in the Biology of Modified Adenovirus vectors.  2nd Annual Meeting of the American Society of Gene Therapy 1999.
• Invited Speaker, Stanford University Dept. of Medical Genetics. Gene Therapy approaches to Genetic Disease.1999
• Invited Speaker, Berlex Industries:   Modification of Adenovirus based vectors for improved efficacy in multiple human diseases.1998.
• Invited Speaker, Brown University Pediatric Grand Rounds: Genetics Update.1998
• Invited Speaker, Michigan State University, Genetics Primer for Primary Care Physicians-1998
• NIH James B. Shannon Award for Promising Young Investigators: (NIH) Sept 1997-1999, “Modified Adenovirus Vectors for Gene Therapy” $50,000/yr.
• Howard Hughes Young Investigator Award-1996
• Diplomate, American Board of Medical Genetics, Clinical Geneticist, 1996, Recert. 2006